211 related articles for article (PubMed ID: 36157769)
21. Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2.
Jasuja H; Chadha N; Kaur M; Silakari O
SAR QSAR Environ Res; 2014; 25(8):617-36. PubMed ID: 25148044
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.
Shu L; Chen C; Huan X; Huang H; Wang M; Zhang J; Yan Y; Liu J; Zhang T; Zhang D
Eur J Med Chem; 2020 Apr; 191():112148. PubMed ID: 32097841
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the janus kinase family increases extracellular signal-regulated kinase 1/2 phosphorylation and causes endoreduplication.
Reiterer G; Yen A
Cancer Res; 2006 Sep; 66(18):9083-9. PubMed ID: 16982750
[TBL] [Abstract][Full Text] [Related]
24. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
25. A hybrid energy-based and AI-based screening approach for the discovery of novel inhibitors of JAK3.
Wei J; Pan Y; Shen Z; Shen L; Xu L; Yu W; Huang W
Front Med (Lausanne); 2023; 10():1182227. PubMed ID: 37886358
[TBL] [Abstract][Full Text] [Related]
26. Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.
Gehringer M; Forster M; Pfaffenrot E; Bauer SM; Laufer SA
ChemMedChem; 2014 Nov; 9(11):2516-27. PubMed ID: 25139757
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives.
Sanachai K; Aiebchun T; Mahalapbutr P; Seetaha S; Tabtimmai L; Maitarad P; Xenikakis I; Geronikaki A; Choowongkomon K; Rungrotmongkol T
RSC Med Chem; 2021 Mar; 12(3):430-438. PubMed ID: 34046625
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L
J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517
[TBL] [Abstract][Full Text] [Related]
29. A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions.
Lin TE; HuangFu WC; Chao MW; Sung TY; Chang CD; Chen YY; Hsieh JH; Tu HJ; Huang HL; Pan SL; Hsu KC
Front Pharmacol; 2018; 9():1379. PubMed ID: 30564118
[TBL] [Abstract][Full Text] [Related]
30. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.
Saharinen P; Silvennoinen O
J Biol Chem; 2002 Dec; 277(49):47954-63. PubMed ID: 12351625
[TBL] [Abstract][Full Text] [Related]
31. Enhancing specificity in the Janus kinases: a study on the thienopyridine JAK2 selective mechanism combined molecular dynamics simulation.
Li JJ; Cheng P; Tu J; Zhai HL; Zhang XY
Mol Biosyst; 2016 Feb; 12(2):575-87. PubMed ID: 26687880
[TBL] [Abstract][Full Text] [Related]
32. Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain.
Hall T; Emmons TL; Chrencik JE; Gormley JA; Weinberg RA; Leone JW; Hirsch JL; Saabye MJ; Schindler JF; Day JE; Williams JM; Kiefer JR; Lightle SA; Harris MS; Guru S; Fischer HD; Tomasselli AG
Protein Expr Purif; 2010 Jan; 69(1):54-63. PubMed ID: 19781647
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1
Liang X; Zang J; Zhu M; Gao Q; Wang B; Xu W; Zhang Y
ACS Med Chem Lett; 2016 Oct; 7(10):950-955. PubMed ID: 27774135
[TBL] [Abstract][Full Text] [Related]
34. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.
Meyer DM; Jesson MI; Li X; Elrick MM; Funckes-Shippy CL; Warner JD; Gross CJ; Dowty ME; Ramaiah SK; Hirsch JL; Saabye MJ; Barks JL; Kishore N; Morris DL
J Inflamm (Lond); 2010 Aug; 7():41. PubMed ID: 20701804
[TBL] [Abstract][Full Text] [Related]
35. Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3).
Poulsen A; William A; Blanchard S; Lee A; Nagaraj H; Wang H; Teo E; Tan E; Goh KC; Dymock B
J Comput Aided Mol Des; 2012 Apr; 26(4):437-50. PubMed ID: 22527961
[TBL] [Abstract][Full Text] [Related]
36. Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors.
Yang M; Tao B; Chen C; Jia W; Sun S; Zhang T; Wang X
J Chem Inf Model; 2019 Dec; 59(12):5002-5012. PubMed ID: 31746601
[TBL] [Abstract][Full Text] [Related]
37. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
38. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
39. Identification of Prognostic Biomarkers and Molecular Targets Among JAK Family in Breast Cancer.
Liu F; Wu H
J Inflamm Res; 2021; 14():97-114. PubMed ID: 33469338
[TBL] [Abstract][Full Text] [Related]
40. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
